On Friday, Delphi Automotive PLC (NYSE:DLPH)’s shares inclined 0.52% to $73.26.
Delphi Automotive PLC (DLPH) will release its third quarter 2015 financial results on Oct. 29 and will hold an investor call the same day at 8:30 a.m. (ET). The call will be hosted by Delphi’s President and Chief Executive Officer, Kevin Clark, and Chief Financial Officer, Mark Murphy.
Delphi Automotive PLC, together with its auxiliaries, manufacturers vehicle components; and provides electrical and electronic, powertrain, safety, and thermal technology solutions to the automotive and commercial vehicle markets worldwide. The company operates through four segments: Electrical/Electronic Architecture, Powertrain Systems, Electronics and Safety, and Thermal Systems.
Pitney Bowes Inc. (NYSE:PBI)’s shares gained 0.80% to $20.12.
Pitney Bowes Inc. (PBI), a global technology company that provides innovative products and solutions to power commerce, declared that Linda Sanford has been elected a director of the corporation. On September 21 the Board expanded its size from 10 to 11 members and her appointment was effective that day to fill the vacancy.
Linda Sanford is a stepped down senior executive of IBM Corporation. She joined IBM in 1975 and was most recently Senior Vice President of Enterprise Transformation. In this role, Ms. Sanford was responsible for working across IBM to transform core business processes, create an IT infrastructure to support and integrate processes globally, and assist create a Values-based culture that fosters innovation. Through her 39 year career at IBM she held a variety of positions of increasing responsibility counting leading IBM’s Global Industries, the organization that manages relationships with IBM’s largest customers worldwide, and Senior Vice President & Group Executive, IBM Storage Systems Group.
Pitney Bowes Inc. provides technology products and solutions in the United States and internationally. The company operates through Small and Medium Business Solutions, Enterprise Business Solutions, and Digital Commerce Solutions segments.
At the end of Friday’s trade, TECO Energy, Inc. (NYSE:TE)‘s shares dipped -0.71% to $26.49.
TECO Energy Inc. (TE) declared that it has closed the sale of its coal mining partner, TECO Coal LLC, to Cambrian Coal Corporation, a Booth Energy company. The sales agreement did not provide for an up-front purchase payment, but does comprise future contingent consideration of $60 million if certain coal benchmark prices reach certain levels over the next five years. TECO Energy retains certain personnel related liabilities, but all other TECO Coal liabilities were transferred in the transaction. The retained liabilities comprised of pension liability, which was fully funded at June 30, 2015, and severance agreements, which were accrued at June 30, 2015.
In the third quarter of 2014 TECO Coal was classified as an asset held for sale, and its operating results have been stated as suspended operations since that time. In addition, through June 30, 2015, TECO Energy has recorded non-cash valuation adjustments of about $128 million, after tax, to the carrying value of TECO Coal, and anticipates that any final closing adjustments will not be material. In the third quarter of 2015, TECO Coal will record a formerly revealed charge in suspended operations of about $8 million, after-tax, related to black lung liabilities.
TECO Energy, Inc., an electric and gas utility holding company, engages in the regulated electric and gas utility operations. It generates purchases, transmits, distributes, and sells electric energy to retail customers, in addition to utilities and other resellers of electricity in West Central Florida; and has electric generating plants with a winter peak generating capacity of 4,668 megawatts.
bluebird bio Inc (NASDAQ:BLUE), ended its Friday’s trading session with -9.74% loss, and closed at $100.21.
bluebird bio, Inc. ( BLUE) declared that members of the administration team will take part in the Leerink Partners Immuno-Oncology Roundtable on Thursday, October 1, 2015, with a fireside chat at 1:30 p.m. ET. The conference is being held at Le Parker Meridien Hotel in New York City.
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic and rare diseases. Its advanced product candidate is Lenti-D, which is in phase II/III clinical studies for the treatment of childhood cerebral adrenoleukodystrophy, a rare, hereditary neurological disorder affecting young boys; and LentiGlobin that is in phase I/II clinical studies for the treatment of beta-thalassemia major and severe sickle cell disease (SCD) in France, in addition to a phase I study in the United States for the treatment of severe SCD.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
